BIRC5 and colorectal cancer: BIRC5 immunotherapy-related clinical trials have been applied in patients with colorectal cancer (Tsuruma et al., 2004), malignant glioma (Fenstermaker et al., 2016), and melanoma (Becker et al., 2012).